Importantly, one Phase II study was designed for analyzing combinatorial effect of HH inhibitor‐vismodegib with FAK inhibitor‐GSK2256098 on progressive meningioma cases (ClinicalTrials.gov Identifier: NCT02523014, first posted:2015), providing the possibility of combination of FAK and Gli1 inhibitors in clinical tumor treatment. Here, PTK2 is linked to neoplasm.